Poolbeg Pharma PLC (POLB) - Total Liabilities
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has total liabilities worth GBX1.34 Million GBX (≈ $163.16 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Poolbeg Pharma PLC - Total Liabilities Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's total liabilities have evolved over time, based on quarterly financial data. See POLB working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Poolbeg Pharma PLC Competitors by Total Liabilities
The table below lists competitors of Poolbeg Pharma PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XXL Energy Corp
V:XL
|
Canada | CA$54.49 Million |
|
Frenkel Topping Group
LSE:FEN
|
UK | GBX18.16 Million |
|
Lucky Minerals Inc
V:LKY
|
Canada | CA$8.19 Million |
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
USA | $554.12 Million |
|
Robert Walters
LSE:RWA
|
UK | GBX213.50 Million |
|
Calnex Solutions Plc
LSE:CLX
|
UK | GBX9.34 Million |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
Sweden | Skr15.38 Million |
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
UK | GBX16.62 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down Poolbeg Pharma PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see POLB market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Poolbeg Pharma PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual total liabilities of Poolbeg Pharma PLC from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX1.34 Million ≈ $163.16 |
+37.68% |
| 2024-12-31 | GBX974.00K ≈ $118.51 |
-1.22% |
| 2023-12-31 | GBX986.00K ≈ $119.97 |
+2.07% |
| 2022-12-31 | GBX966.00K ≈ $117.53 |
+120.55% |
| 2021-12-31 | GBX438.00K ≈ $53.29 |
-- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more